Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$4.7 million.

  • Zevra Therapeutics' Change in Accured Expenses fell 13792.76% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.0 million, marking a year-over-year decrease of 8532.92%. This contributed to the annual value of -$3.6 million for FY2024, which is 13232.7% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Change in Accured Expenses is -$4.7 million, which was down 13792.76% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Change in Accured Expenses registered a high of $7.0 million during Q4 2024, and its lowest value of -$7.3 million during Q1 2024.
  • In the last 5 years, Zevra Therapeutics' Change in Accured Expenses had a median value of -$189000.0 in 2021 and averaged -$339421.1.
  • In the last 5 years, Zevra Therapeutics' Change in Accured Expenses tumbled by 41058.02% in 2021 and then skyrocketed by 88930.04% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Change in Accured Expenses (Quarter) stood at $778000.0 in 2021, then surged by 140.23% to $1.9 million in 2022, then surged by 206.58% to $5.7 million in 2023, then rose by 22.02% to $7.0 million in 2024, then plummeted by 167.65% to -$4.7 million in 2025.
  • Its Change in Accured Expenses was -$4.7 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$7.3 million in Q1 2025.